Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.81 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138629 | 0.88 | FGFR1 (1.00) | FGFR1ALDH1A1 | |
| SCHEMBL14308878 | 0.87 | FGFR1 (0.71) | FGFR1SLC22A6POLBHPRT1 | |
| SCHEMBL23292842 | 0.81 | FGFR1 (0.68) | FGFR1 | |
| SCHEMBL24140186 | 0.80 | FGFR1 (0.68) | FGFR1 | |
| SCHEMBL24140174 | 0.80 | FGFR1 (0.68) | FGFR1 | |
| SCHEMBL24140143 | 0.80 | FGFR1 (0.68) | FGFR1 | |
| SCHEMBL26803955 | 0.79 | FGFR1 (0.65) | FGFR1HPRT1 | |
| SCHEMBL24140146 | 0.79 | FGFR1 (0.66) | FGFR1 | |
| SCHEMBL10047653 | 0.79 | FGFR1 (0.74) | FGFR1SLC22A6POLBHPRT1 | |
| SCHEMBL26803959 | 0.78 | FGFR1 (0.63) | FGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012031045-A2 | PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF | CHIMERIX, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-8017135-B1 | Lipid-drug conjugates for local therapy of eye diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-13 | — | — | US | disclosed |
| US-7790703-B2 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | FGFR1 1923/4885SLC22A6 2635/4885KDM4E 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.